Revalesio partners with leading firm

October 21, 2010

By Flinn Foundation

[Source: GEN] – Revalesio Corporation announced today that it has contracted with Predictive Biomarker Sciences (PBS-Bio) to conduct studies related to the use of Revalesio’s novel anti-inflammatory therapeutic in treating cancer.

To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work and identifies biomarkers that can help predict which patients will respond to treatment.

For more information: Revalesio Partners with Leading Firm